Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tuberculosis vaccines: current progress.

Ian M Orme1

  • 1Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado 80523, USA. ian.orme@colostate.edu

Drugs
|November 22, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BCG-Prime and boost with Esx-5 secretion system deletion mutant leads to better protection against clinical strains of Mycobacterium tuberculosis.

Vaccine·2020
Same author

Trying to See the Forest through the Trees: Deciphering the Nature of Memory Immunity to <i>Mycobacterium tuberculosis</i>.

Frontiers in immunology·2018
Same author

Biology of clinical strains of Mycobacterium tuberculosis with varying levels of transmission.

Tuberculosis (Edinburgh, Scotland)·2018
Same author

GI-19007, a Novel Saccharomyces cerevisiae-Based Therapeutic Vaccine against Tuberculosis.

Clinical and vaccine immunology : CVI·2017
Same author

Pillars Article: The Kinetics of Emergence and Loss of Mediator T Lymphocytes Acquired in Response to Infection with <i>Mycobacterium Tuberculosis</i>. <i>J. Immunol</i>. 1987. 138: 293-298.

Journal of immunology (Baltimore, Md. : 1950)·2017
Same author

Mouse and Guinea Pig Models of Tuberculosis.

Microbiology spectrum·2016
Same journal

Ecnoglutide: First Approvals.

Drugs·2026
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
See all related articles

New tuberculosis vaccines are urgently needed due to drug resistance. Research focuses on T-helper-1 immunity and animal models to evaluate promising vaccine candidates like subunit, DNA, and vector-based options.

Area of Science:

  • Immunology
  • Vaccinology
  • Infectious Diseases

Background:

  • Tuberculosis (TB) remains a significant global health burden, particularly in developing nations.
  • Emerging drug resistance and limited pharmaceutical investment necessitate novel TB control strategies.
  • Understanding the host immune response, specifically T-helper-1 immunity, is crucial for effective vaccine development.

Purpose of the Study:

  • To highlight the pressing need for new tuberculosis vaccines.
  • To discuss the importance of T-helper-1 immunity in host resistance against TB.
  • To review current approaches and promising candidates for TB vaccine development.

Main Methods:

  • Utilizing animal models, primarily mice and guinea pigs, for vaccine efficacy assessment.

Related Experiment Videos

  • Employing short-term prophylactic models involving vaccination followed by aerosol challenge.
  • Measuring the reduction in lung bacterial load as a key indicator of vaccine protection.

    • Main Results:

    • Several promising vaccine types have been identified, including subunit, DNA, and live vector-based vaccines.
    • Recombinant bacillus Calmette-Guérin (BCG) and modified Mycobacterium tuberculosis strains show potential.
    • Some novel vaccine candidates have advanced to early-stage clinical trials.

    Conclusions:

    • The development of new tuberculosis vaccines is a critical priority.
    • Inducing a T-helper-1 immune response is essential for effective host resistance.
    • Ongoing research and clinical trials are exploring innovative vaccine strategies to combat TB.